Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

HIV Testing Certification

23 Mar 2012 07:00

RNS Number : 9058Z
BATM Advanced Communications Ld
23 March 2012
 



23 March 2012

 

BATM Advanced Communications Limited

CE certification for HIV screening kit

 

BATM Advanced Communications Limited ("the Company") (LSE: BVC), a leading designer and producer of broadband data and telecoms systems and medical laboratory equipment, is delighted to announce that its fully owned subsidiary Adaltis, a manufacturer of medical diagnostics equipment, has received CE certification for its Detect HIV 4th generation (AIDS 4th generation ) Total Screening Kit.

The kit is able to detect simultaneously HIV 1&2 antibodies and HIV p24 antigens, with the 4th generation screening able to detect the latest strains of the virus. Testing in external, independent labs has shown performance results of 100% accuracy for diagnostic sensitivity and 99.7% for diagnostic specifity, clearly marking this screening kit as the top of its class. This level of accuracy will ensure that patients receive reliable diagnosis and that laboratories are spared the significant and needless expense of repeat testing.

Initial deliveries of the new kit will start in the second quarter of this year, with an increasing buildup of production through the fourth quarter and into next year.

Dr Zvi Marom, Chief Executive, of BATM commented:

"The sensitivity and specifity performance levels of our Total Screening Kit are clearly outstanding and we are delighted to have received CE certification. We have received great interest in this product and certification now allows us to increase sales in several territories.

"This important step in our medical division augurs well for its future with the prospect of improved margins and sales. The Company is encouraged that its success with this kit will extend to other kits that are under certifications."

 

- Ends -

For further information:

Enquiries

BATM Advanced Communications +972 9866 2527Ofer Bar-Ner, CFO

Newgate Threadneedle 020 7653 9850Josh Royston / Graham Herring

finnCap 020 7220 0500Marc Young / Brian Patient

Shore Capital 020 7408 4090 Pascal Keane

Notes to Editors

According to a report in January 2012 from TriMarkPublications.com, there are an estimated 33.3 million people living with HIV worldwide and approximately 2.6 million people are newly infected each year. Although the Asian and African regions account for more than 90% of the HIV-infected population, the U.S. and European regions make up greater than 60% of the HIV testing market.

The same report also states that the global HIV-AIDS testing market is forecasted to catapult to $4.4 billion by 2016.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEDFMEFESESD
Date   Source Headline
26th May 20267:00 amRNSBlock Listing Interim Review
21st Apr 20267:00 amRNSPublication of Annual Report
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 202612:00 pmRNSHolding(s) in Company
10th Feb 20267:00 amRNSSale of Non-core Business
3rd Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RBATM selected as FPT Israel cybersecurity partner
12th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20267:00 amRNSHolding(s) in Company
8th Jan 202611:00 amRNSTransaction in own shares and Total Voting Rights
2nd Jan 20267:01 amRNSDirector Declaration
2nd Jan 20267:01 amRNSDirector Declaration
2nd Jan 20267:00 amRNSCompletion of Sale of Diagnostics Distributor
2nd Jan 20267:00 amRNSCompletion of Sale of Diagnostics Distributor
29th Dec 20257:00 amRNSAppointment of Chairman and Directorate Change
29th Dec 20257:00 amRNSAppointment of Chairman and Directorate Change
10th Dec 202512:00 pmRNSAGM Result, Directorate Change & AMS Sale Update
1st Dec 20257:00 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSBlock Listing Interim Review
17th Nov 20257:00 amRNSNew Carrier Ethernet Order
5th Nov 20257:00 amRNSNotice of AGM and Directorate Changes
6th Oct 20257:00 amRNSSale of Diagnostics Distributor
26th Sep 20257:00 amRNSDirectorate Change
18th Aug 20257:00 amRNSInterim Results
4th Aug 20257:00 amRNSTotal Voting Rights
24th Jul 20257:00 amRNSSale of Non-Core Businesses and Notice of Results
23rd Jun 20257:00 amRNSDirectorate Change
27th May 20257:00 amRNSBlock Listing Interim Review
12th May 20257:00 amRNSOrder for ultra-high speed encryption development
6th May 20257:00 amRNS-RBATM unveils new brand identity
8th Apr 202511:00 amRNSAnnual Report Publication and AGM Update Statement
27th Mar 20257:00 amRNSNew strategic customer for Edgility in Brazil
17th Mar 20257:00 amRNSFull Year Results
5th Mar 20257:00 amRNSUpdate on Strategy and Trading
24th Feb 20257:00 amRNSHolding(s) in Company
16th Jan 20257:00 amRNSADOR appoints Nadhim Zahawi to lead Advisory Board
19th Dec 20243:30 pmRNSResult of AGM and Director Appointment
19th Dec 20247:00 amRNSNew Tier 1 Customer for Edgility in Mexico
11th Dec 20247:00 amRNSNATlab commences pre-clinical validation
3rd Dec 20247:00 amRNSBlock Listing Interim Review
2nd Dec 20247:00 amRNSBATM receives orders of $2.4m for Edgility
25th Nov 20247:00 amRNSBlock listing Interim Review
14th Nov 202411:00 amRNSNotice of AGM and Proposed Director Appointment
4th Nov 20247:00 amRNSTotal Voting Rights
19th Aug 20247:00 amRNSInterim Results
10th Jul 20247:00 amRNSAmazon Web Services partnership for Edgility
2nd Jul 20247:00 amRNSCommercial markets cybersecurity partnership
3rd Jun 20247:00 amRNSBlock Listing Interim Review
28th May 20247:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.